TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

NCT04074343 PHASE1 COMPLETED Results posted

This is a phase Ib single-arm, open-label clinical trial determining the feasibility and efficacy of TAS-102 and irinotecan in subjects with advanced gastric and gastroesophageal adenocarcinoma. These are subjects who are not candidates for curative treatments and who have received at least one prior line of chemotherapy with a fluoropyrimidine and platinum agent.

Details

Lead sponsor	University of California, Irvine
Phase	PHASE1
Status	COMPLETED
Enrolment	20
Start date	Mon Aug 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jul 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Gastric Adenocarcinoma
• GastroEsophageal Cancer

Interventions

• TAS-102
• Irinotecan

Countries

United States